Safety of Daiobotampito in the Treatment of Acute Diverticulitis of the Colon: A Single-Center, Open-Label, Prospective Trial.
The purpose of this study was to investigate the safety of daiobotampito in the treatment of acute diverticulitis of the colon. We conducted a single-center, open-label, prospective study. Ten patients who suffered from diverticulitis of the colon were recruited. The patients were treated with fasting, antibacterial agents, and daiobotampito extract for 10 days in or out of hospital. The patients individually recorded their body temperature, grade of abdominal pain, number of times that analgesics were used, and number of stools daily. We checked whether the patients had adverse reactions such as abdominal pain or diarrhea. No patients experienced serious adverse reactions. One patient had moderate abdominal pain and diarrhea soon after daiobotampito intake. This patient discontinued daiobotampito on day 4, and the pain and diarrhea quickly resolved. The abdominal pain of this patient was worse 6 days before treatment, and the pain was almost relieved with initial daiobotampito treatment. Daiobotampito is a safe treatment option for early stage, acute diverticulitis.